Crenezumab

Disease Target Area: Alzheimers

About the Disease:

Alzheimer’s disease leads to nerve cell death and tissue loss throughout the brain. Over time, the brain shrinks dramatically, affecting nearly all its functions. The disease affects nearly six million people in the United States and about 50 million globally. With a growing aging population, the Centers for Disease Control and Prevention projects the burden of Alzheimer’s disease will nearly triple to 14 million people by 2060.

About the Program & What we learned:

Crenezumab is still being studied in familial Alzheimer’s Disease in a study in a unique cohort in Colombia in which treatment is started before the onset of cognitive decline. The Phase 3 studies in sporadic Alzheimer’s disease, in which patients were enrolled early in disease (but after symptom onset) were recently stopped but the team is still currently analyzing data and there will be more insights to come.